In May 2024, Novo Holdings, a Denmark-based company specializing in life science, acquired Catalent for a deal of $16.5 billion
GLP-1 microdosing is suitable for: Individuals at risk for chronic diseases (cardiovascular, neurological, renal) Those pursuing longevity or preventive health measures Patients seeking sustainable wellness beyond weight loss Consultation with your doctor is required to confirm eligibility
In the pursuit of improved longevity, men have long sought after various remedies and solutions
And that compounding list the panel just voted for
The Bottom Line Patients should have clear information about what these drugs can and cannot do, along with proper medical supervision that goes beyond just tracking weight, looking at muscle mass, nutrition, and overall health
Messaging that focuses on high protein and lean meat will appeal to these consumers